Skip to main content
. Author manuscript; available in PMC: 2019 Jan 17.
Published in final edited form as: ACS Chem Neurosci. 2017 Nov 7;9(1):51–72. doi: 10.1021/acschemneuro.7b00271

Table 1.

Therapeutic interventions in brain neoplasms and the observed outcomes.

Therapy Target Outcome +/− Model Ref.
Temozolomide + doxorubicin P-gp Increased survival + Rats 263
Palbociclib CDK4/6 Activity limited by P-gp Mice 264
LIUS P-gp and MDR1 Apoptosis and CNS delivery + Rats and C6 cells 266
FGK45 CD40 Increased survival
Decreased proliferation
+ Mice 267
γ9δ2 T cells IFN γ Increased cytotoxicity + GBM cells 268
miROPN OPN Less stem cell markers
Less proliferation
Increased survival
+ Mice 270
CAR-transduced T cells PDPN Inhibition of intracranial glioma xenografts growth + Mice 273
LRIG1 Oncogenic receptor tyrosine kinases Slowing of tumor growth. Apoptosis + Mice 275
VB-111 Endothelial cells Decreased tumor vasculature and growth + Rats 276
Decorin EGFR, TGF- beta and p21 Cellular differentiation
Survival
+ Mice 278
HDAC6i HDAC6 Increased survival + Mice 280
oHSV nectin-1 (CD111) Increased cytotoxicity + Pediatric patients 281
HDACi + Delta24-RGD HDAC and p16INK4/Rb pathway Apoptosis and necrosis + Patient-derived GSCs 282
PDNCs CNS delivery Increased trans-BBB delivery and CNS retention time + Rats 284
Lf/FA/PLGA NPs VEGF secretion Less proliferation + U87MG cells 285
C-SLN CNS delivery Improved delivery and cytotoxicity + Mice 286
RDG CNS delivery Increased delivery and CNS retention + Mice 287
HA-paclitaxel nanoconjugate Microtubules Survival + Mice 288
VD3NPs combined with doxorubicin or epirobicin Sphingomyelin pathway Increase in drug resistance C6 glioma cells 290

+ indicates a favorable outcome.

−indicates an unfavorable outcome.